Skip to main content

Market Overview

Glaukos: What Data Points Really Matter?

Share:
Glaukos: What Data Points Really Matter?

Piper Jaffray said it values Glaukos Corp (NYSE: GKOS)'s suprachoroidal stent in development at $175 million based on Alcon's announcement that it paid $352 million for Glaukos competitor, Transcend, which also has a similar product.

Analyst Matt O'Brien said Transcend's CyPass Stent is placed in the suprachoroidal space in the eye, while Glaukos also has a suprachoroidal stent in the pipeline that is expected in 2019.

"The disclosure that Alcon paid such a large price for Transcend, in our opinion, is just further evidence of the value GKOS is creating," the analyst wrote in a note.

Related Link: Stifel Sees Near-Term Concerns At Glaukos Overshadowing Long-Term Bullishness

Glaukos, which specializes in glaucoma treatment, has a product called iStent in Schlemm's canal for reducing introcular pressure (IOP). The company claims that iStent is the only FDA-approved device for the treatment of mild to moderate open-angle glaucoma.

Meanwhile, Glaukos is also developing a device that goes in to the suprachoroidal to relieve IOP.

"Thus assuming a similar value to Transcend (one product currently) and discounting the purchase price three years by 25 percent yields a present value of $175 million for the product GKOS has in development. That alone is ~33 percent of GKOS' current EV and doesn't even account for other products (in our view larger opportunities) Inject and iDose," O'Brien noted.

The analyst reiterated his Overweight rating and increased the price target by $2 to $21.

Latest Ratings for GKOS

DateFirmActionFromTo
Apr 2021OppenheimerUpgradesPerformOutperform
Jan 2021Piper SandlerDowngradesOverweightNeutral
Dec 2020CitigroupUpgradesSellNeutral

View More Analyst Ratings for GKOS
View the Latest Analyst Ratings

 

Related Articles (GKOS)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech Health Care Price Target Reiteration Top Stories Analyst Ratings Trading Ideas Best of Benzinga

Latest Ratings

StockFirmActionPT
QSRNorthcoast ResearchInitiates Coverage On
DQGLJ ResearchInitiates Coverage On22.1
TCMaxim GroupDowngrades
GLNGB of A SecuritiesDowngrades
LMNXPiper SandlerDowngrades37.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com